Trial
NCT03483883
Avelumab/Gemcitabine in Sarcomatoid RCC
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
—
Condition
Metastatic sRCC
Intervention
Avelumab
Why stopped
The study was terminated due to protracted accrual and limited patient engagement in the setting of rapidly changing treatment paradigms for advanced RCC with sarcomatoid features and/or intermediate/poor risk clinical features.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-26